Physician profile
Christopher Navas
NPI 1861846081
$2,951.07
in general payments reported to CMS, 2019-2025
25 companies · $935 in 2025
The $935 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $99.00 · 2022: $380 · 2023: $800 · 2024: $737 · 2025: $935.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,472.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,471.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $723.38 | 2022-2025 | |
| Janssen Biotech, INC. | $498.93 | 2020-2025 | Tremfya, Stelara, Remicade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $495.75 | 2022-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $239.67 | 2022-2025 | Entyvio, Gattex |
| Regeneron Healthcare Solutions, INC. | $171.32 | 2022-2025 | Dupixent |
| Madrigal Pharmaceuticals | $143.92 | 2025 | Rezdiffra |
| Aimmune Therapeutics, INC. | $117.15 | 2024-2025 | Zenpep |
| Gilead Sciences, INC. | $69.95 | 2024-2025 | |
| Qol Medical, LLC | $62.95 | 2023 | Sucraid |
| Genzyme Corporation | $57.44 | 2023-2025 | |
| Ipsen Biopharmaceuticals, INC | $51.95 | 2024-2025 | Iqirvo |
| Pharmacosmos Therapeutics INC. | $40.92 | 2025 | Monoferric |
| Lilly USA, LLC | $29.27 | 2024 | Omvoh |
| Enterra Medical, INC. | $27.90 | 2024 | |
| Apollo Endosurgery US INC | $25.39 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $24.80 | 2025 | Givlaari |
| Boston Scientific Corporation | $23.52 | 2025 | Overstitch Endoscopic Suturing System |
| Novo Nordisk INC | $21.63 | 2025 | Wegovy |
| Braintree Laboratories, INC. | $19.97 | 2022 | |
| Pfizer INC. | $19.56 | 2025 | |
| Ironwood Pharmaceuticals, INC | $19.35 | 2023 | Linzess |
| Ardelyx, INC. | $18.55 | 2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $17.72 | 2025 | Voquezna |
| Redhill Biopharma INC. | $15.57 | 2022 | |
| Celgene Corporation | $14.51 | 2023 | Zeposia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Navas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.